NUEDEXTA is the first and only
FDA-approved treatment for PBA1
The efficacy and safety of NUEDEXTA was studied in patients diagnosed with
pseudobulbar affect (PBA).
Get the latest point of care resources, including real PBA patient stories and provider perspectives.
Patients with neurologic conditions including but not limited to stroke, dementia, traumatic brain injury (TBI), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), or multiple sclerosis (MS) may also be struggling with involuntary, sudden, frequent episodes of laughing and/or crying—treatable symptoms suggestive of PBA.1-4
PBA has a substantial impact on patients
PBA adds an additional disease burden to patients already suffering from a serious neurologic disorder.5
Do you know the symptoms of PBA?
Symptoms are frequent, sudden, uncontrollable laughing and/or crying outbursts.6 In relation to mood, episodes may be incongruent or, commonly, exaggerated.1